Semax: The Complete Guide
A seven-amino-acid peptide developed in Russia in the 1980s. Research suggests it triples BDNF expression in the hippocampus — the brain's primary growth factor for learning and memory — while leaving cortisol completely unaffected. One of the most extensively studied nootropic peptides in the literature.
What is Semax?
Here is the simplest way to understand Semax: your brain has a protein called BDNF — brain-derived neurotrophic factor — that does for brain cells what fertiliser does for plants. BDNF helps neurons grow, form new connections, and survive. It is the underlying biology of learning and memory. Research suggests Semax tells the brain to produce more of this growth factor. A single dose has been research-suggested to triple BDNF mRNA expression in the hippocampus within hours, alongside an increase in BDNF protein and the receptor (TrkB) that BDNF uses to signal.
Semax is a synthetic heptapeptide developed in Russia in the 1980s, jointly by the Institute of Molecular Genetics of the Russian Academy of Sciences and Moscow State University. The name itself is a Russian abbreviation meaning "seven amino acids" (С-Е-М-ь А-К-с). The peptide is built from a small fragment of a hormone called ACTH (specifically residues 4-7), with a stabilising three-amino-acid tail (Pro-Gly-Pro) added to the end. Research suggests this design preserves the neurotrophic activity of the original ACTH fragment while making the peptide stable enough to do meaningful work.
What sets Semax apart is the unusual combination of evidence behind it. The molecule has been on the Russian List of Vital and Essential Drugs since 2011 — meaning it is a prescribed medication in Russia for stroke recovery, traumatic brain injury, optic nerve disease, and cognitive decline. More than two decades of clinical use in Russia produces a real-world evidence base most research peptides simply do not have. At the same time, it is not approved by the FDA, EMA, or TGA. The bulk of the published research originates from Russian institutions, which is part of why Semax remains a research compound in most of the world even though it is a clinically used drug in its country of origin. The honest framing is that the evidence base is substantial but geographically concentrated.
Research Applications
Research on Semax spans the BDNF/neurotrophin pathway that drives most of its cognitive activity, the post-stroke neuroprotection studies that supported the Russian clinical approval, and the more recent transcriptomic analyses examining how Semax shifts gene expression patterns after cerebral ischaemia.
Research suggests a single dose of Semax produces approximately a 3-fold increase in BDNF mRNA in the hippocampus within hours of administration, alongside increased BDNF protein and TrkB receptor expression. BDNF is the primary protein driving synaptic plasticity and long-term potentiation — the cellular machinery underlying learning and memory.
On the Russian List of Vital and Essential Drugs since 2011 for ischaemic stroke recovery, traumatic brain injury, optic nerve disease, and cognitive decline. Research suggests the underlying mechanism involves shifting brain gene expression away from inflammation and toward neurotransmission and repair after ischaemic injury.
Research has examined effects on learning, memory, and selective attention across animal and human studies. Research suggests improvements through fundamental neurotrophic support rather than through sympathetic arousal — the mechanism is structural rather than stimulant.
Research suggests Semax also modulates serotonergic and dopaminergic activity in the brain. Picture the BDNF effect as building the underlying brain infrastructure, while the neurotransmitter modulation tunes the real-time signalling that infrastructure carries.
Despite being derived from ACTH (the hormone that normally tells the adrenal glands to release cortisol), research suggests Semax does not stimulate cortisol production. The ACTH(4-7) fragment used as Semax's backbone lacks the regions of full-length ACTH responsible for adrenal stimulation. Neurotrophic activity preserved; hormonal cascade absent.
Prescribed clinically in Russia and CIS countries since the early 2000s. The accumulated real-world clinical evidence base across more than 20 years of use produces a safety record that few research peptides can match — though Western regulatory approval has not been pursued.
How Semax Works
The big-picture answer first: Semax works through several overlapping mechanisms, but the central story is BDNF upregulation. Research suggests the peptide tells the brain to produce more of its main growth factor, which strengthens the cellular machinery underlying learning, memory, and neuronal survival. The other mechanisms (neurotransmitter modulation, anti-inflammatory gene expression) layer on top of this central effect.
BDNF and the TrkB receptor in plain language: BDNF is one of the most abundant and important growth factors in the brain. Picture neurons as plants — BDNF is the fertiliser that helps them grow, branch, form new connections, and survive when conditions are stressful. BDNF signals through a receptor called TrkB. When BDNF binds TrkB, it activates downstream pathways (MAPK/ERK, PI3K/Akt, PLC-gamma) that drive synaptic strengthening, dendrite growth, and the formation of new neural connections. Research suggests Semax upregulates both BDNF itself and the TrkB receptor in the hippocampus — meaning the brain produces more growth factor, and the cells are better equipped to receive it.
The 3-fold finding in context: the headline Semax research finding comes from a 2006 Brain Research paper (Dolotov and colleagues). A single dose of Semax produced an approximately 3-fold increase in BDNF mRNA expression in the rat hippocampus, alongside an approximately 1.4-fold increase in BDNF protein and a comparable increase in TrkB. The mRNA-vs-protein gap is normal in molecular biology — mRNA changes happen first, protein changes follow. What matters is that within hours of a single administration, the brain was producing substantially more growth factor signalling, and the receptors to receive that signalling were also upregulated. Subsequent research suggests this effect extends beyond BDNF to other neurotrophins (NGF, NT-3) and their receptors (TrkA, TrkC) — a broader neurotrophic signature than most compounds in the cognitive research family produce.
Neurotransmitter modulation: alongside the BDNF effect, research suggests Semax modulates serotonergic and dopaminergic systems in the brain. This is mechanistically different from how stimulants work. Stimulants drive neurotransmitter release through sympathetic arousal — more output, more crash. Research suggests Semax instead supports balanced neurotransmitter activity by improving the underlying neurotrophic biology of the cells producing those neurotransmitters. The mechanism is structural; the result is sustained rather than spike-and-crash.
Why no cortisol despite the ACTH origin: full-length ACTH is the hormone that tells the adrenal glands to release cortisol. The cortisol-stimulating activity of ACTH lives in different regions of the molecule than the neurotrophic activity. Research suggests Semax's backbone (ACTH 4-7) contains the neurotrophic-active region but lacks the adrenal-stimulating regions. This is the central pharmacological insight that allowed Russian researchers to develop Semax in the first place — the same parent hormone produces two completely different activities depending on which fragment you isolate.
Transcriptomic effects after stroke: more recent research using genome-wide RNA sequencing (Dergunova and colleagues, 2014 and 2020) has examined how Semax shifts gene expression patterns in the brain after cerebral ischaemia. Research suggests ischaemic injury normally activates inflammatory genes and suppresses neurotransmission genes — the molecular signature of brain damage. Research suggests Semax produces the opposite pattern: suppressing inflammatory gene activation and supporting neurotransmission gene expression. This compensatory pattern is the proposed mechanistic basis for the Russian clinical use in stroke recovery.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated April 2026.
Published References
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain research, 2006. PubMedThe foundational BDNF paper — the study that established the central mechanism story. Research suggests a single dose of Semax produced an approximately 3-fold increase in BDNF mRNA in the rat hippocampus alongside increased BDNF protein and TrkB receptor. The most important single paper for understanding why Semax sits at the centre of the cognitive cluster.
- Dmitrieva VG, Povarova OV, Skvortsova VI, et al. “Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.” Cellular and molecular neurobiology, 2010. PubMedExtended the neurotrophic story beyond BDNF alone — research suggests Semax (and its Pro-Gly-Pro tail working independently) activates transcription of multiple neurotrophin family members (BDNF, NGF, NT-3) and their receptors after ischaemic injury. Important for understanding why Semax has a broader neurotrophic signature than most cognitive research compounds.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC genomics, 2014. PubMedA genome-wide RNA-Seq study examining how Semax shifts gene expression patterns after stroke in research models. Research suggests Semax suppresses inflammatory gene activation while supporting neurotransmission gene expression — a compensatory pattern that may underlie the Russian clinical use in stroke recovery.
- Filippenkov IB, Stavchansky VV, Denisova AE, et al. “Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats.” Genes, 2020. PubMedA more recent transcriptomic study extending the 2014 findings to ischaemia-reperfusion models. Useful for understanding how Semax's gene-expression effects vary with the type of cerebral injury — and how the compensatory anti-inflammatory pattern holds across different research models.
Browse all Semax research on PubMed →
Related Research Guides
More in Bioregulators & Neuropeptides
Sister peptide from the same Russian research institute — same Pro-Gly-Pro stabilising tail, but built around the tuftsin sequence instead of ACTH. Research suggests Selank targets GABA pathways for anxiety research, while Semax targets BDNF for cognitive research. Designed to be complementary.
Read guide →TREK-1 Channel InhibitorA short peptide targeting the TREK-1 potassium channel — a different angle on cognitive and mood research from Semax's neurotrophin pathway. Research suggests TREK-1 inhibition supports neurogenesis and synaptic plasticity through a separate mechanism.
Read guide →Evidence and publication statusAn angiotensin IV-derived compound whose evidence includes a retracted mechanism paper and an earlier expression of concern. Read the updated evidence limitations.
Read guide →